-
Je něco špatně v tomto záznamu ?
Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation
J. Stetka, P. Vyhlidalova, L. Lanikova, P. Koralkova, J. Gursky, A. Hlusi, P. Flodr, S. Hubackova, J. Bartek, Z. Hodny, V. Divoky,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- cytokiny genetika metabolismus MeSH
- fosfatasa 1 s dvojí specificitou genetika MeSH
- hematopoetické kmenové buňky patologie MeSH
- indukované pluripotentní kmenové buňky patologie MeSH
- Janus kinasa 2 genetika MeSH
- lidé MeSH
- mutace MeSH
- nádorové buněčné linie MeSH
- nádorové mikroprostředí MeSH
- oxidační stres * MeSH
- polycythaemia vera genetika MeSH
- poškození DNA * MeSH
- proliferace buněk * MeSH
- reprodukovatelnost výsledků MeSH
- transkripční faktor STAT1 metabolismus MeSH
- zánět metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Inflammatory and oncogenic signaling converge in disease evolution of BCR-ABL-negative myeloproliferative neoplasms, clonal hematopoietic stem cell disorders characterized by gain-of-function mutation in JAK2 kinase (JAK2V617F), with highest prevalence in patients with polycythemia vera (PV). Despite the high risk, DNA-damaging inflammatory microenvironment, PV progenitors tend to preserve their genomic stability over decades until their progression to post-PV myelofibrosis/acute myeloid leukemia. Using induced pluripotent stem cells-derived CD34+ progenitor-enriched cultures from JAK2V617F+ PV patient and from JAK2 wild-type healthy control, CRISPR-modified HEL cells and patients' bone marrow sections from different disease stages, we demonstrate that JAK2V617F induces an intrinsic IFNγ- and NF-κB-associated inflammatory program, while suppressing inflammation-evoked DNA damage both in vitro and in vivo. We show that cells with JAK2V617F tightly regulate levels of inflammatory cytokines-induced reactive oxygen species, do not fully activate the ATM/p53/p21waf1 checkpoint and p38/JNK MAPK stress pathway signaling when exposed to inflammatory cytokines, suppress DNA single-strand break repair genes' expression yet overexpress the dual-specificity phosphatase (DUSP) 1. RNAi-mediated knock-down and pharmacological inhibition of DUSP1, involved in p38/JNK deactivation, in HEL cells reveals growth addiction to DUSP1, consistent with enhanced DNA damage response and apoptosis in DUSP1-inhibited parental JAK2V617F+ cells, but not in CRISPR-modified JAK2 wild-type cells. Our results indicate that the JAK2V617F+ PV progenitors utilize DUSP1 activity as a protection mechanism against DNA damage accumulation, promoting their proliferation and survival in the inflammatory microenvironment, identifying DUSP1 as a potential therapeutic target in PV.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006468
- 003
- CZ-PrNML
- 005
- 20200525102435.0
- 007
- ta
- 008
- 200511s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41388-019-0813-7 $2 doi
- 035 __
- $a (PubMed)30967632
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Stetka, J $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 245 10
- $a Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation / $c J. Stetka, P. Vyhlidalova, L. Lanikova, P. Koralkova, J. Gursky, A. Hlusi, P. Flodr, S. Hubackova, J. Bartek, Z. Hodny, V. Divoky,
- 520 9_
- $a Inflammatory and oncogenic signaling converge in disease evolution of BCR-ABL-negative myeloproliferative neoplasms, clonal hematopoietic stem cell disorders characterized by gain-of-function mutation in JAK2 kinase (JAK2V617F), with highest prevalence in patients with polycythemia vera (PV). Despite the high risk, DNA-damaging inflammatory microenvironment, PV progenitors tend to preserve their genomic stability over decades until their progression to post-PV myelofibrosis/acute myeloid leukemia. Using induced pluripotent stem cells-derived CD34+ progenitor-enriched cultures from JAK2V617F+ PV patient and from JAK2 wild-type healthy control, CRISPR-modified HEL cells and patients' bone marrow sections from different disease stages, we demonstrate that JAK2V617F induces an intrinsic IFNγ- and NF-κB-associated inflammatory program, while suppressing inflammation-evoked DNA damage both in vitro and in vivo. We show that cells with JAK2V617F tightly regulate levels of inflammatory cytokines-induced reactive oxygen species, do not fully activate the ATM/p53/p21waf1 checkpoint and p38/JNK MAPK stress pathway signaling when exposed to inflammatory cytokines, suppress DNA single-strand break repair genes' expression yet overexpress the dual-specificity phosphatase (DUSP) 1. RNAi-mediated knock-down and pharmacological inhibition of DUSP1, involved in p38/JNK deactivation, in HEL cells reveals growth addiction to DUSP1, consistent with enhanced DNA damage response and apoptosis in DUSP1-inhibited parental JAK2V617F+ cells, but not in CRISPR-modified JAK2 wild-type cells. Our results indicate that the JAK2V617F+ PV progenitors utilize DUSP1 activity as a protection mechanism against DNA damage accumulation, promoting their proliferation and survival in the inflammatory microenvironment, identifying DUSP1 as a potential therapeutic target in PV.
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a proliferace buněk $7 D049109
- 650 _2
- $a cytokiny $x genetika $x metabolismus $7 D016207
- 650 12
- $a poškození DNA $7 D004249
- 650 _2
- $a fosfatasa 1 s dvojí specificitou $x genetika $7 D054638
- 650 _2
- $a hematopoetické kmenové buňky $x patologie $7 D006412
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a indukované pluripotentní kmenové buňky $x patologie $7 D057026
- 650 _2
- $a zánět $x metabolismus $7 D007249
- 650 _2
- $a Janus kinasa 2 $x genetika $7 D053614
- 650 _2
- $a mutace $7 D009154
- 650 12
- $a oxidační stres $7 D018384
- 650 _2
- $a polycythaemia vera $x genetika $7 D011087
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a transkripční faktor STAT1 $x metabolismus $7 D050794
- 650 _2
- $a nádorové mikroprostředí $7 D059016
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vyhlidalova, P $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Lanikova, L $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Laboratory of Cell and Developmental Biology, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic.
- 700 1_
- $a Koralkova, P $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Gursky, J $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Hlusi, A $u Department of Hemato-Oncology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Flodr, P $u Department of Clinical and Molecular Pathology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Hubackova, S $u Laboratory of Molecular Therapy, Institute of Biotechnology, BIOCEV, Czech Academy of Sciences, Prague-West, 252 50, Czech Republic.
- 700 1_
- $a Bartek, J $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. jb@cancer.dk. Danish Cancer Society Research Center, DK-2100, Copenhagen, Denmark. jb@cancer.dk. Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic. jb@cancer.dk. Division of Genome Biology, Department of Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden. jb@cancer.dk.
- 700 1_
- $a Hodny, Z $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic. zdenek.hodny@img.cas.cz.
- 700 1_
- $a Divoky, V $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. vladimir.divoky@upol.cz. Department of Hemato-Oncology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. vladimir.divoky@upol.cz.
- 773 0_
- $w MED00003600 $t Oncogene $x 1476-5594 $g Roč. 38, č. 28 (2019), s. 5627-5642
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30967632 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200525102436 $b ABA008
- 999 __
- $a ok $b bmc $g 1525326 $s 1096524
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 38 $c 28 $d 5627-5642 $e 20190409 $i 1476-5594 $m Oncogene $n Oncogene $x MED00003600
- LZP __
- $a Pubmed-20200511
